Pheochromocytoma News and Research

RSS

Pheochromocytoma is a term used to refer to rare and mostly benign catecholamine-secreting tumors arising from the chromaffin cells found in the adrenal medulla or in the paraganglia (i.e. extra-adrenal pheochromocytoma). Clinical presentation can be highly variable and can mimic other diseases, but the condition typically presents with hypertension, palpitations, severe headaches, and sweating.

Scientists develop noninvasive way to monitor gene expression dynamics in the brain

Researchers introduced a non-invasive, sensitive method for monitoring gene expression in the brain using engineered reporters called released markers of activity, which can exit the brain into the blood for easy detection.

12 Jan 2024

Unlocking radiation resistance: Missing protein key to suppressing cancer-fighting cells

A new study finds that radiation therapy (RT) suppresses a key protein called bone morphogenetic protein and activin membrane-bound inhibitor (BAMBI) and activates immune suppressive cells.

15 Dec 2023

Mediterranean diet and the modulation of mitochondrial function

Researchers reviewed the current knowledge related to the Mediterranean diet (MedDiet) and the role of mitochondria concerning health outcomes.

7 Apr 2023

Largest genomic study focuses on the prognosis of metastatic pheochromocytomas

Pheochromocytoma is a rare tumor, with an incidence of three to eight cases per million population per year.

28 Feb 2023

New strategies to beat rare tumors of the adrenal gland

Only one in 100,000 people suffer from a pheochromocytoma, a tumor of the adrenal gland. If the tumor has already metastasized, a radioactive compound can be used to detect malignant cells that have spread to other parts of the body, and to irradiate them from the inside.

9 Feb 2023

Study investigates the prevalence of adrenal tumors in an unselected screening population

A cross-sectional study of more than 25,000 adults has found that with increased screening, the prevalence of adrenal tumors in an unselected community population was 1.4%. The prevalence increased with age, from 0.2% in adults aged 18 to 25 up to 3.2% in adults older than 65 years of age. However, approximately 70% of identified tumors were nonfunctioning, meaning they did not make extra hormones, regardless of the participant's age. The findings are published in Annals of Internal Medicine.

13 Sep 2022

Treatment resistance for deadly form of kidney cancer linked to low mitochondrial content in the cell

Researchers at Karolinska Institutet in Sweden have linked resistance to treatment for a deadly form of kidney cancer to low mitochondrial content in the cell.

27 Jun 2022

High prevalence of germline variants in Japanese patients with pheochromocytoma and paraganglioma

Certain kinds of tumors can be inherited within families. Identifying the underlying genetic cause is important in treatment, but most studies on these tumors have been carried out on Caucasian populations.

19 Nov 2021

Sunitinib extends progression-free survival in patients with rare neuroendocrine tumor, study shows

The first randomized study in malignant pheochromocytoma and paraganglioma (MPP) has found that sunitinib prolongs progression-free survival (PFS) by more than five months.

20 Sep 2021

Immunotherapy treatment shows promise for some patients with advanced rare cancers

A study conducted by researchers at The University of Texas MD Anderson Cancer Center demonstrated acceptable toxicity and anti-tumor activity in patients with four types of advanced, hard-to-treat rare cancers.

20 Mar 2020

NETRF announces $3.5 million in research grants to improve neuroendocrine tumor treatment

The Neuroendocrine Tumor Research Foundation, Boston, MA, today announced $3.5 million in neuroendocrine tumor research grants to fund 12 projects around the world in pursuit of more precise treatments for this uncommon cancer affecting an estimated 171,000 Americans.

12 Feb 2020

FDA approves first nasal glucagon therapy for treatment of severe hypoglycemia

The U.S. Food and Drug Administration today approved Baqsimi nasal powder, the first glucagon therapy approved for the emergency treatment of severe hypoglycemia that can be administered without an injection.

24 Jul 2019

Novel radiotracer can identify nearly 30 types of malignant tumors

A novel class of radiopharmaceuticals has proven effective in non-invasively identifying nearly 30 types of malignant tumors, according to research published in the June issue of The Journal of Nuclear Medicine.

10 Jun 2019

FDA approves first ever non-surgical treatment for rare neuroendocrine cancers

The U.S. Food and Drug Administration has approved the first ever non-surgical treatment for the rare neuroendocrine cancers pheochromocytoma and paraganglioma.

31 Jul 2018

FDA approves first therapy for patients with rare tumors of the adrenal gland

The U.S. Food and Drug Administration today approved Azedra (iobenguane I 131) injection for intravenous use for the treatment of adults and adolescents age 12 and older with rare tumors of the adrenal gland (pheochromocytoma or paraganglioma) that cannot be surgically removed (unresectable), have spread beyond the original tumor site and require systemic anticancer therapy.

31 Jul 2018

YCC researchers suggest promising treatment for two rare inherited cancer syndromes

Studying two rare inherited cancer syndromes, Yale Cancer Center scientists have found the cancers are driven by a breakdown in how cells repair their DNA.

17 Jul 2018

Radiotherapy drug used for treating rare neuroendocrine cancers can be safe, effective for patients

A radiotherapy drug that treats the rare neuroendocrine cancers pheochromocytoma and paraganglioma can be both effective and safe for patients, according to the findings of a multi-center trial led by researchers in the Abramson Cancer Center of the University of Pennsylvania.

30 May 2018

Study identifies new mutations linked to hereditary neuroendocrine tumors

Pheochromocytomas and paragangliomas are rare neuroendocrine tumors with a strong hereditary component. Half the genes whose alterations confer hereditary susceptibility to develop this condition code for enzymes involved in the Krebs cycle, a metabolic route involved in cellular respiration.

20 Jul 2017

Lilly Diabetes releases Android version of Glucagon Mobile App to support diabetes caregivers

Lilly Diabetes has released an Android version of its mobile application designed for caregivers and healthcare providers who support people with diabetes. Through an injection tutorial and emergency instructions, the App can help people practice the injection steps ahead of time, which may help them feel better prepared to assist.

15 Jul 2015

Concordia Healthcare's common shares to begin trading on NASDAQ under symbol CXRX

Concordia Healthcare Corp., a diverse healthcare company focused on legacy pharmaceutical products and orphan drugs, today announced that its common shares will begin trading on the NASDAQ Global Select Market on June 29, 2015 under the symbol CXRX.

25 Jun 2015